|
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2. |
|
|
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals |
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate |
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation |
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals |
|
|
Research Funding - BN ImmunoTherapeutics; GlaxoSmithKline; Janssen; Medivation; Sanofi |
|
|
Research Funding - Tokai Pharmaceuticals |
|
|
Employment - Tokai Pharmaceuticals |
Leadership - Baxalta; Progenics; Tokai Pharmaceuticals |
Stock and Other Ownership Interests - Baxalta; Progenics; Tokai Pharmaceuticals |
|
|
Research Funding - Carolina Clinical Trials |
|
|
Employment - Tokai Pharmaceuticals |
Stock and Other Ownership Interests - Tokai Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Dendreon; Sanofi |
Consulting or Advisory Role - Agensys |
Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst) |